CTLA-4 Control over Foxp3 + Regulatory T Cell Function
The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Naturally occurring Foxp3+CD4+ regulatory T cells (Tregs) are essential for maintaining immunological self-tolerance and immune homeostasis. Here, we show that a specific deficiency of cytotoxic T lymphocyte antigen 4 (CTLA-4) in Tregs results in spontaneous development of systemic lymphoproliferation, fatal T cell-mediated autoimmune disease, and hyperproduction of immunoglobulin E in mice, and it also produces potent tumor immunity. Treg-specific CTLA-4 deficiency impairs in vivo and in vitro suppressive function of Tregs-in particular, Treg-mediated down-regulation of CD80 and CD86 expression on dendritic cells. Thus, natural Tregs may critically require CTLA-4 to suppress immune responses by affecting the potency of antigen-presenting cells to activate other T cells.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The central role that CTLA-4 plays in immunological tolerance is exemplified by experiments in mice that lack the CTLA-4 gene globally or specifically in the Forkhead box P3 (FoxP3)+ Treg compartment. These animals develop lymphoproliferative disorders and die at a young age (25, 26).”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [25]
In the citing paper
“Indeed, this process is an important mechanism by which Tregs mediate immune suppression on bystander cells (25).”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [25]
In the citing paper
“Of note, although CTLA4 blockade was shown to cause selective depletion of intratumoral Tregs through antibody-dependent cell-mediated cytotoxicity (ADCC) in murine models and ex vivo experiments on human tumor samples (24)(25)(26),”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [24]
In the citing paper
“The CTLA-4 regulatory effects mainly temper the activation of CD4+ helper T cells while boosting regulatory T cells (Tregs) (Doyle et al., 2001; Wing et al., 2008), leading to a pro-tumor immunosuppressive phenotype.”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Wing et al., 2008
Citations
Cites
Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls
The Wellcome Trust Case Control Consortium, Management Committee, Burton, P. R., Clayton, D. G., Cardon, L. R., Craddock, N., Deloukas, P., Duncanson, A., Kwiatkowski, D. P., McCarthy, M. I., et al. (2007) · Nature · doi:10.1038/nature05911 · Cited by 9,442
Control of Regulatory T Cell Development by the Transcription Factor Foxp3
Hori, S., Nomura, T., & Sakaguchi, S. (2003) · Science · doi:10.1126/science.1079490 · Cited by 8,187
Self-citationRegulatory T Cells and Immune Tolerance
Sakaguchi, S., Yamaguchi, T., Nomura, T., & Ono, M. (2008) · Cell · doi:10.1016/j.cell.2008.05.009 · Cited by 5,325
Self-citationEnhancement of Antitumor Immunity by CTLA-4 Blockade
Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955
Tivol, E. A., Borriello, F., Schweitzer, A. N., Lynch, W. P., Bluestone, J. A., & Sharpe, A. H. (1995) · Immunity · doi:10.1016/1074-7613(95)90125-6 · Cited by 2,914
Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4
Waterhouse, P., Penninger, J. M., Timms, E., Wakeham, A., Shahinian, A., Lee, K. P., Thompson, C. B., Griesser, H., & Mak, T. W. (1995) · Science · doi:10.1126/science.270.5238.985 · Cited by 2,766
Takahashi, T., Tagami, T., Yamazaki, S., Uede, T., Shimizu, J., Sakaguchi, N., Mak, T. W., & Sakaguchi, S. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.303 · Cited by 2,233
Self-citationRead, S., Malmström, V., & Powrie, F. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.295 · Cited by 2,205
Salomon, B., Lenschow, D. J., Rhee, L., Ashourian, N., Singh, B., Sharpe, A., & Bluestone, J. A. (2000) · Immunity · doi:10.1016/s1074-7613(00)80195-8 · Cited by 2,081
Phan, G. Q., Yang, J. C., Sherry, R. M., Hwu, P., Topalian, S. L., Schwartzentruber, D. J., Restifo, N. P., Haworth, L. R., Seipp, C. A., Freezer, L. J., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1533209100 · Cited by 1,575
Research works printed but not linked: 1
- 10.1002/1521-4141(200006)30:6<1538::aid-immu1538>3.0.co;2-x · doi:10.1002/1521-4141(200006)30:6<1538::aid-immu1538>3.0.co;2-x
Cited by
Items 901–1,000 of 1,010
The role of CD4+ T cells in tumor and chronic viral immune responses
Xie, L., Fang, J., Yu, J., Zhang, W., He, Z., Ye, L., & Wang, H. (2023) · MedComm · doi:10.1002/mco2.390 · Cited by 62
Ishimoto, T., Shimada, M., Gabriela, G., Kosugi, T., Sato, W., Lee, P. Y., Lanaspa, M. A., Rivard, C. J., Maruyama, S., Garin, E. H., et al. (2012) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfs543 · Cited by 61
“One such modulator is CTLA-4, a costimulatory receptor for CD80, which can be secreted by T reg cells as a soluble isoform and is known to down-regulate CD80 on antigen-presenting cells [10, 11].”
BackgroundThe Impact of the Tumor Microenvironment on the Properties of Glioma Stem-Like Cells
Audia, A., Conroy, S., Glaß, R., & Bhat, K. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00143 · Cited by 62
Alsughayyir, J., Pettigrew, G. J., & Motallebzadeh, R. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01639 · Cited by 61
“Conventional FoxP3 regulatory CD4 T cells (Tregs), as well as CD8 regulatory T cells (257, 258), are also necessary for prevention of humoral autoimmunity, likely through their inhibitory impact on the TFH cell population.”
BackgroundThe CD28–B7 Family of Co-signaling Molecules
Nagai, S., & Azuma, M. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-981-32-9717-3_2 · Cited by 62
T cell costimulation, checkpoint inhibitors and anti-tumor therapy
Nandi, D., Pathak, S., Verma, T., Singh, M., Chattopadhyay, A., Thakur, S., Raghavan, A., Gokhroo, A., & Vijayamahantesh, V. (2020) · Journal of Biosciences · doi:10.1007/s12038-020-0020-2 · Cited by 61
Targeting regulatory T cells for immunotherapy in melanoma
Huang, L., Guo, Y., Liu, S., Wang, H., Zhu, J., Ou, L., & Xu, X. (2021) · Molecular Biomedicine · doi:10.1186/s43556-021-00038-z · Cited by 61
“Treg depletion by anti-CTLA-4 mAbs decreases the immunosuppression in the TME, but it also results in severe cancer immunotherapy-related adverse events [59].”
BackgroundThe role of T regulatory cells in human sepsis
Kessel, A., Bamberger, E., Masalha, M., & Toubi, E. (2009) · Journal of Autoimmunity · doi:10.1016/j.jaut.2009.02.014 · Cited by 63
The Role of the Basic Helix-Loop-Helix Transcription Factor Dec1 in the Regulatory T Cells
Miyazaki, K., Miyazaki, M., Guo, Y., Yamasaki, N., Kanno, M., Honda, Z.-I., Oda, H., Kawamoto, H., & Honda, H. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1001381 · Cited by 61
Turning the Tide Against Regulatory T Cells
Han, S., Toker, A., Liu, Z. Q., & Ohashi, P. S. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00279 · Cited by 61
Environmental Triggering of Type 1 Diabetes Autoimmunity
Houeiss, P., Luce, S., & Boîtard, C. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.933965 · Cited by 61
“Preproinsulin (PPI) epitopes that are presented by different HLA class I molecules to CD8+ T-cells and by HLA class II molecules to CD4+ T-cells have been characterized (17).”
BackgroundInfluentialWatanabe, T., Ishino, T., Ueda, Y., Nagasaki, J., Sadahira, T., Dansako, H., Araki, M., & Togashi, Y. (2023) · Cancer Science · doi:10.1111/cas.15756 · Cited by 60
Teng, Y.-S., & Yu, S. (2023) · Current Oncology · doi:10.3390/curroncol30070498 · Cited by 61
“Therefore, the loss of CTLA-4 may result in massive lymphoproliferation, profound T cell-mediated autoimmunity, and fatal multiorgan tissue destruction [3,27,28].”
BackgroundPlomp, L., Chassepot, H., Psimaras, D., Maisonobe, T., Mensi, E., Léonard-Louis, S., Plu, I., Rozes, A., Tubach, F., Touat, M., et al. (2025) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2024.101192 · Cited by 60
“…for oculo-bulbo-* Introduction “ Immune checkpoints ” constitute immuno-inhibitory signaling pathways that mediate negative regulation of T-cell activation (e.g., induction of T-cell anergy – for maintenance of peripheral tolerance, 1 – 4 or in the context of tumor cells, immune evasion).”
Lerret, N. M., Houlihan, J. L., Kheradmand, T., Pothoven, K. L., Zhang, Z. J., & Luo, X. (2012) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2012.04120.x · Cited by 60
“CTLA-4 is known to play an important role in Treg function (23).”
BackgroundImmunotherapeutic Advancements for Glioblastoma
Ampie, L., Woolf, E. C., & Dardis, C. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00012 · Cited by 60
“Additionally, this immune-checkpoint protein has been shown to enhance the suppressive function of TReg cells (34, 35).”
BackgroundBilliard, F., Buard, V., Benderitter, M., & Linard, C. (2011) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2010.12.041 · Cited by 60
Rivas, M. N., Koh, Y. T., Chen, A., Nguyen, A., Lee, Y. H., Lawson, G., & Chatila, T. A. (2012) · Journal of Clinical Investigation · doi:10.1172/jci40591 · Cited by 55
Pathogenesis of childhood idiopathic nephrotic syndrome: a paradigm shift from T-cells to podocytes
Kaneko, K., Tsuji, S., Kimata, T., Kitao, T., Yamanouchi, S., & Kato, S. (2015) · World Journal of Pediatrics · doi:10.1007/s12519-015-0003-9 · Cited by 60
López‐Abente, J., Correa‐Rocha, R., & Pion, M. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00192 · Cited by 60
“Of note are Sakaguchi’s findings, where he demonstrated that nTreg-specific CTLA-4 deficiency or CTLA-4 blockade using anti-CTLA-4, impaired or abrogated nTreg-suppressive function in vivo and in vitro, respectively (14, 16).”
BackgroundImbalance between the anti- and pro-inflammatory milieu in blood leukocytes of autistic children
Ahmad, S. F., Nadeem, A., Ansari, M. A., Bakheet, S. A., Attia, S. M., Zoheir, K. M. A., AL-Ayadhi, L. Y., Alzahrani, M. Z., Alsaad, A. M. S., Alotaibi, M. R., et al. (2016) · Molecular Immunology · doi:10.1016/j.molimm.2016.12.019 · Cited by 61
Patsoukis, N., Weaver, J. D., Strauss, L., Herbel, C., Seth, P., & Boussiotis, V. A. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00330 · Cited by 60
“T cell activation is initiated by recognition of antigens presented by antigen-presenting cells (APCs) to the T cell receptor (TCR)–CD3 complex in the presence of CD28 costimulation.”
BackgroundInfluentialHistone Deacetylation Inhibitors as Modulators of Regulatory T Cells
von Knethen, A., Heinicke, U., Weigert, A., Zacharowski, K. D., & Brüne, B. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21072356 · Cited by 62
Chen, J., Yang, J., Li, H., Yang, Z., Zhang, X., Li, X., Wang, J., Zhang, Y., Chen, S., & Song, M. (2021) · Molecular Oncology · doi:10.1002/1878-0261.12910 · Cited by 61
Lin, C., Wu, C.-J., Cho, S., Patkar, R., Huth, W. J., Lin, L.-L., Chen, M., Israelsson, E., Betts, J., Niedzielska, M., et al. (2023) · Nature Immunology · doi:10.1038/s41590-023-01667-y · Cited by 59
Napolitano, M., D’Alterio, C., Cardone, E., Trotta, A. M., Pecori, B., Rega, D., Pace, U., Scala, D., Scognamiglio, G., Tatangelo, F., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3014 · Cited by 59
FOXP3+ regulatory T cells: control of FOXP3 expression by pharmacological agents
Ohkura, N., Hamaguchi, M., & Sakaguchi, S. (2011) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2010.12.004 · Cited by 60
Self-citationT cell coinhibition in prostate cancer: new immune evasion pathways and emerging therapeutics
Barach, Y. S., Lee, J. S., & Zang, X. (2010) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2010.09.006 · Cited by 59
Comparative effect of 25(OH)D3 and 1,25(OH)2D3 on Th17 cell differentiation
Fawaz, L. M., Mrad, M. F., Kazan, J. M., Sayegh, S., Akika, R., & Khoury, S. J. (2016) · Clinical Immunology · doi:10.1016/j.clim.2016.02.011 · Cited by 60
TCR Signaling and CD28/CTLA-4 Signaling Cooperatively Modulate T Regulatory Cell Homeostasis
Holt, M. P., Punkosdy, G. A., Glass, D. D., & Shevach, E. M. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1601670 · Cited by 59
“modulating Treg function has been shown to include a cell-intrinsic mechanism controlling TCR signaling (20), along with several distinct cell-extrinsic mechanisms (21, 22), including competition with CD28 on Tconv cells for CD80/CD86 signaling (23, 24), negatively signaling APCs via CD80/CD86 (25), and actively remov…”
BackgroundLiver X receptor activation promotes differentiation of regulatory T cells
Herold, M. V. B., Breuer, J., Hucke, S., Knolle, P. A., Schwab, N., Wiendl, H., & Klotz, L. (2017) · PLoS ONE · doi:10.1371/journal.pone.0184985 · Cited by 59
Common Features of Regulatory T Cell Specialization During Th1 Responses
Lambert, K., Moresi, C., Rakebrandt, N., Zhou, X., Schorer, M., Dolowschiak, T., Kirchner, F., Rost, F., Keller, C. W., McHugh, D., et al. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01344 · Cited by 59
“Upon Th1-dominated infectious challenge with different classes of pathogens, which included viral infections with high and low type I IFN responses and a bacterial pathogen, Treg cells become highly activated and we could observe an induction of a multitude of classical suppressive mediators expressed in Treg cells su…”
BackgroundInfluentialMatoba, T., Imai, M., Ohkura, N., Kawakita, D., Ijichi, K., Toyama, T., Morita, A., Murakami, S., Sakaguchi, S., & Yamazaki, S. (2018) · International Journal of Cancer · doi:10.1002/ijc.32024 · Cited by 59
Self-citationHelminth infections drive heterogeneity in human type 2 and regulatory cells
de Ruiter, K., Jochems, S. P., Tahapary, D. L., Stam, K. A., König, M. H., van Unen, V., Laban, S., Höllt, T., Mbow, M., Lelieveldt, B. P. F., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aaw3703 · Cited by 59
Control of foreign Ag‐specific Ab responses by Treg and Tfr
Wing, J. B., Lim, E. L., & Sakaguchi, S. (2020) · Immunological Reviews · doi:10.1111/imr.12888 · Cited by 59
Self-citationRegulatory T cells: Master thieves of the immune system
Akkaya, B., & Shevach, E. M. (2020) · Cellular Immunology · doi:10.1016/j.cellimm.2020.104160 · Cited by 59
Therapeutic applications of the cancer immunoediting hypothesis
Desai, R. R., Coxon, A. T., & Dunn, G. P. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.03.002 · Cited by 59
Kos, K., Aslam, M. A., van de Ven, R., Wellenstein, M. D., Pieters, W., van Weverwijk, A., Duits, D. E. M., van Pul, K., Hau, C., Vrijland, K., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110447 · Cited by 60
Duncan, B., Nazarov–Stoica, C., Surls, J., Kehl, M., Bona, C. A., Casares, S. A., & Brumeanu, T. (2010) · PLoS ONE · doi:10.1371/journal.pone.0011427 · Cited by 59
“High intracellular CTLA-4 expression (iCTLA-4) is increased in the CD4Foxp3 Tregulatory (T-reg) cells, and it synergizes with their suppressogenic function [49].”
BackgroundIntratumoral Anti-CTLA-4 Therapy: Enhancing Efficacy While Avoiding Toxicity
Marabelle, A., Kohrt, H. E. K., & Levy, R. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1923 · Cited by 59
Inhibitory receptor agonists: the future of autoimmune disease therapeutics?
Grebinoski, S., & Vignali, D. A. (2020) · Current Opinion in Immunology · doi:10.1016/j.coi.2020.06.001 · Cited by 58
HMG-CoA reductase promotes protein prenylation and therefore is indispensible for T-cell survival
Lacher, S. M., Bruttger, J., Kalt, B., Berthelet, J., Rajalingam, K., Wörtge, S., & Waisman, A. (2017) · Cell Death & Disease · doi:10.1038/cddis.2017.221 · Cited by 58
“31) (made available to our group by Dr. Ernesto Bockamp, Mainz) and Foxp3-IRES-cre.32 All strains were kept on the C57BL/6 background.”
BackgroundSplicing factor SRSF1 is indispensable for regulatory T cell homeostasis and function
Katsuyama, T., & Moulton, V. R. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109339 · Cited by 58
Modulating Co-Stimulation During Antigen Presentation to Enhance Cancer Immunotherapy
Liechtenstein, T., Dufait, I., Lanna, A., Breckpot, K., & Escors, D. (2012) · Immunology Endocrine & Metabolic Agents - Medicinal Chemistry · doi:10.2174/187152212802001875 · Cited by 60
“On the other hand, CD80/86 can also engage inhibitory receptors on T cells such as the cytotoxic T-lymphocyte antigen 4 (CTLA4), and deliver inhibitory signals leading to anergic T cells or Tregs (Figure 1) [15].”
BackgroundInfluentialAutoimmune thyroiditis: A model uniquely suited to probe regulatory T cell function
Kong, Y.-C. M., Morris, G. P., Brown, N. K., Yan, Y., Flynn, J. C., & David, C. S. (2009) · Journal of Autoimmunity · doi:10.1016/j.jaut.2009.09.004 · Cited by 59
Immunogenicity of biotherapeutics in the context of developing biosimilars and biobetters
Barbosa, M. D. F. S. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2011.01.011 · Cited by 58
A Monovalent Anti-Human CD28 Domain Antibody Antagonist: Preclinical Efficacy and Safety
Suchard, S. J., Davis, P. M., Kansal, S., Stetsko, D. K., Brosius, R., Tamura, J. K., Schneeweis, L. A., Bryson, J. W., Salcedo, T. W., Wang, H., et al. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1300470 · Cited by 58
“In contrast, CTLA-4 expression on Tregs is important for the suppression of autoreactive T cells and the prevention of in vivo autoimmunity (19).”
Backgroundγδ T Cells in Cancer Immunotherapy: Current Status and Future Prospects
Chiplunkar, S. V., Dhar, S., Wesch, D., & Kabelitz, D. (2009) · Immunotherapy · doi:10.2217/imt.09.27 · Cited by 60
Regulatory T Cells in HIV Infection: Can Immunotherapy Regulate the Regulator?
Jenabian, M.-A., Ancuța, P., Gilmore, N. J., & Routy, J. (2012) · Clinical and Developmental Immunology · doi:10.1155/2012/908314 · Cited by 58
Combination Treatment With Anti-CD20 and Oral Anti-CD3 Prevents and Reverses Autoimmune Diabetes
Hu, C., Ding, H., Zhang, X., Wong, F. S., & Li, W. (2013) · Diabetes · doi:10.2337/db12-1175 · Cited by 60
“CTLA-4 has been implicated in the control of CD4Foxp3 Treg function (37).”
BackgroundRecent success and limitations of immune checkpoint inhibitors for cancer: A lesson from melanoma
Ottaviano, M., De Placido, S., & Ascierto, P. A. (2019) · Virchows Archiv · doi:10.1007/s00428-019-02538-4 · Cited by 57
Immunotherapy of pancreatic cancer
Sunami, Y., & Kleeff, J. H. (2019) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2019.03.006 · Cited by 57
Immune Checkpoints in Cancers: From Signaling to the Clinic
Pisibon, C., Ouertani, A., Bertolotto, C., Ballotti, R., & Chéli, Y. (2021) · Cancers · doi:10.3390/cancers13184573 · Cited by 58
“Meanwhile Treg cells express CTLA-4 constitutively, and this molecule participates in the maintenance of tolerance applied by Treg cells [29,30].”
BackgroundThe paradox of immune checkpoint inhibition re-activating tuberculosis
Ahmed, M. I. M., Tezera, L. B., Elkington, P. T., & Leslie, A. J. (2022) · European Respiratory Journal · doi:10.1183/13993003.02512-2021 · Cited by 57
Li, R., Li, H., Yang, X., Hu, H., Liu, P., & Liu, H. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.970508 · Cited by 57
“(51) have suggested that CTLA-4 is necessary for Tregs to exert an inhibitory effect, whereas Paterson et al.”
BackgroundInfluentialCTLA-4-expressing ILC3s restrain interleukin-23-mediated inflammation
Ahmed, A., Joseph, A. M., Zhou, J., Horn, V., Uddin, J., Lyu, M., Goc, J., Bank, J. L. C., Artis, D., Longman, R., et al. (2024) · Nature · doi:10.1038/s41586-024-07537-3 · Cited by 58
Self-citationT Follicular Helper Cells During Immunity and Tolerance
Linterman, M. A., & Vinuesa, C. G. (2010) · Progress in molecular biology and translational science · doi:10.1016/s1877-1173(10)92009-7 · Cited by 57
Garden, O. A., Pinheiro, D., & Cunningham, F. M. (2010) · International Immunopharmacology · doi:10.1016/j.intimp.2010.11.003 · Cited by 57
Preclinical development of T cell receptor gene therapy
Bendle, G. M., Haanen, J. B. A. G., & Schumacher, T. N. (2009) · Current Opinion in Immunology · doi:10.1016/j.coi.2009.02.007 · Cited by 57
New therapeutic strategies for malignant pleural mesothelioma
Bonelli, M. A., Fumarola, C., Monica, S. L., & Alfieri, R. R. (2016) · Biochemical Pharmacology · doi:10.1016/j.bcp.2016.07.012 · Cited by 57
“The distinction between the secondary lymphoid organs or peripheral localization and role of CTLA-4 and PD-1 respectively is not absolute, indeed CTLA-4 plays also a relevant role in the regulation of the suppressive function of T regulatory (Treg) lymphocytes, that are typically localized in tumor tissues and are tho…”
BackgroundA New VISTA on combination therapy for negative checkpoint regulator blockade
Deng, J., Mercier, I. L., Kuta, A., & Noelle, R. J. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0190-5 · Cited by 57
“Import-antly, the absence of CTLA-4 specifically on Tregs is sufficient for the development of autoimmunity, further reiterating the major role of CTLA-4 in Treg mediated suppression [16].”
BackgroundCharacterization of CTLA4 Trafficking and Implications for Its Function
Khailaie, S., Rowshanravan, B., Robert, P. A., Waters, E., Halliday, N., Herrera, J. D. B., Walker, L. S. K., Sansom, D. M., & Meyer‐Hermann, M. (2018) · Biophysical Journal · doi:10.1016/j.bpj.2018.08.020 · Cited by 57
Importance of lymph node immune responses in MSI-H/dMMR colorectal cancer
Inamori, K., Togashi, Y., Fukuoka, S., Akagi, K., Ogasawara, K., Irie, T., Motooka, D., Kobayashi, Y., Sugiyama, D., Kojima, M., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.137365 · Cited by 57
“…CD45RA – FOXP3 lo CD4 + ) without a suppressive function (Figure 5A) (24, 26, 27). eTregs have higher expression of CTLA-4 — which is an important immune checkpoint molecule and plays a crucial role in Treg-mediated immune suppression (28) — than that of FOXP3 lo non-Tregs (Supplemental Figure 8).”
The biologic importance of tumor‐infiltrating lymphocytes
Hodi, F. S., & Dranoff, G. (2010) · Journal of Cutaneous Pathology · doi:10.1111/j.1600-0560.2010.01506.x · Cited by 58
Halpert, M. M., Konduri, V., Liang, D., Chen, Y., Wing, J. B., Paust, S., Levitt, J. M., & Decker, W. K. (2016) · Stem Cells and Development · doi:10.1089/scd.2016.0009 · Cited by 57
Berezhnoy, A., Sumrow, B. J., Stahl, K., Shah, K., Liu, D., Li, J., Hao, S.-S., De Costa, A., Kaul, S., Bendell, J., et al. (2020) · Cell Reports Medicine · doi:10.1016/j.xcrm.2020.100163 · Cited by 56
“Knockout of CTLA-4 in Tregs does not affect their survival, but it does eliminate their suppressive function.(3) When expressed by T lymphocytes, among other cells, PD-1 acts as an inhibitory molecule that reduces cytotoxicity and cytokine production.”
BackgroundGan, X., Shan, Q., Li, H., Janssens, R., Shen, Y., He, Y., Chen, F., van Haperen, R., Drabek, D., Li, J., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2200879119 · Cited by 57
Partial dysfunction of Treg activation in sickle cell disease
Vingert, B., Tamagne, M., Desmarets, M., Pakdaman, S., Elayeb, R., Habibi, A., Bernaudin, F., Galactéros, F., Bierling, P., Pirenne, F., et al. (2014) · American Journal of Hematology · doi:10.1002/ajh.23629 · Cited by 56
“In addition to the direct effect of Treg on T-cell function, Treg can modulate the maturation and function of DC [19,20].”
BackgroundRegulation of the tolerogenic function of steady‐state DCs
Probst, H. C., Muth, S., & Schild, H. (2014) · European Journal of Immunology · doi:10.1002/eji.201343862 · Cited by 56
Alteration of Regulatory T Cells in Type 1 Diabetes Mellitus: A Comprehensive Review
Tan, T., Xiang, Y., Chang, C. C., & Zhou, Z. (2014) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-014-8440-0 · Cited by 57
“CLTA4 expressed by Tregs downregulates DC’s expression of CD80 and CD86 and thereby inhibits the activation of Teffs [42, 43].”
BackgroundBeavis, P. A., Gregory, B., Green, P. A., Cribbs, A. P., Kennedy, A., Amjadi, P., Palfreeman, A. C., Feldmann, M., & Brennan, F. M. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1112722108 · Cited by 56
“3 illustrates the molecules associated with Treg activity (29, 30) after stimulation with either anti-CD3 or the cytokine mixture with analysis restricted to the foxp3 subset of activated cells (Fig.”
MethodAref, S., Azmy, E., & El‐Gilany, A. (2015) · Hematological Oncology · doi:10.1002/hon.2206 · Cited by 56
“Several molecules have been reported for contact-dependent inhibition mechanism, such as CTLA-4 (inhibits antigen presenting cells), lymphocyte activation gene 3 (induces inhibitory signal through MHC II molecules), granzymes (mediate lysis of conventional T cells) and CD95-CD95L (induces apoptosis in conventional T c…”
BackgroundImmune checkpoint blockade: Releasing the brake towards hematological malignancies
Xia, Y., Medeiros, L. J., & Young, K. H. (2015) · Blood Reviews · doi:10.1016/j.blre.2015.11.003 · Cited by 56
“Target depletion of CTLA-4 in FOXP3-expressing cells also leads to a fatal T cell-mediated autoimmune disease that resembles what was observed in CTLA-4 deficientmice [14, 15].”
ResultInducing and Administering Tregs to Treat Human Disease
Perdigoto, A. L., Chatenoud, L., Bluestone, J. A., & Herold, K. C. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00654 · Cited by 49
Cancer immune checkpoint blockade therapy and its associated autoimmune cardiotoxicity
Zhang, J.-C., Chen, W., Alvarez, J. B., Jia, K. Q., Shi, L., Wang, Q., Zou, N., He, K., & Zhu, H. (2018) · Acta Pharmacologica Sinica · doi:10.1038/s41401-018-0062-2 · Cited by 57
Mechanisms of checkpoint inhibition-induced adverse events
Urwyler, P., Earnshaw, I., Bermudez, M., Perucha, E., Wu, W., Ryan, S. E., Mcdonald, L., Karagiannis, S. N., Taams, L. S., Powell, N., et al. (2020) · Clinical & Experimental Immunology · doi:10.1111/cei.13421 · Cited by 56
Rojas, C., Campos‐Mora, M., Cárcamo, I., Villalón, N., Elhusseiny, A., Contreras‐Kallens, P., Refisch, A., Gálvez‐Jirón, F., Emparán, I., Montoya-Riveros, A., et al. (2020) · Journal of Leukocyte Biology · doi:10.1002/jlb.3mr0420-533rr · Cited by 56
Autoimmune Endocrinopathies: An Emerging Complication of Immune Checkpoint Inhibitors
Quandt, Z., Young, A., Perdigoto, A. L., Herold, K. C., & Anderson, M. S. (2020) · Annual Review of Medicine · doi:10.1146/annurev-med-050219-034237 · Cited by 56
Shaping of T Cell Functions by Trogocytosis
NAKAYAMA, M., Hori, A., Toyoura, S., & Yamaguchi, S.-I. (2021) · Cells · doi:10.3390/cells10051155 · Cited by 57
“Treg-specific CTLA-4 deletion indicates that Treg CTLA-4 is crucial for immune suppression [123].”
BackgroundSchwarz, A., & Schwarz, T. (2010) · Journal of Investigative Dermatology · doi:10.1038/jid.2010.59 · Cited by 56
“, 2008) and downregulate B7-1 and B7-2 but not MHC class II on DCs (Wing et al., 2008).”
BackgroundToussirot, É., Saas, P., Deschamps, M., Pouthier, F., Perrot, L., Perruche, S., Chabod, J., Tiberghien, P., & Wendling, D. (2009) · Arthritis Research & Therapy · doi:10.1186/ar2747 · Cited by 56
“On the other hand, CTLA-4 is absolutely required for the suppressive function of naturally occurring FoxP3+ Treg, at least in mice [10].”
BackgroundImmune checkpoint inhibitors associated cardiovascular immune-related adverse events
Jo, W., Won, T., Daoud, A., & Čiháková, D. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1340373 · Cited by 55
“Furthermore, multiple studies have indicated CTLA-4 ’ s role in maintaining peripheral heart tolerance (42, 111, 151 – 155).”
BackgroundSakaguchi, S., Kawakami, R., & Mikami, N. (2023) · Immunotherapy Advances · doi:10.1093/immadv/ltad007 · Cited by 56
“Upon antigenic stimulation, Tregs further up-regulate the expression of CTLA-4, which not only competes with CD28 for binding to CD80/CD86 but also down-regulates the expression of CD80/CD86 on antigenpresenting cells (APCs) via trogocytosis and subsequent transendocytosis of CTLA-4-bound CD80/CD86 to Treg cell membra…”
Self-citationOkamoto, N., Noma, T., Ishihara, Y., Miyauchi, Y., Takabatake, W., Oomizu, S., Yamaoka, G., Ishizawa, M., Namba, T., Murakami, K., et al. (2014) · International Heart Journal · doi:10.1536/ihj.13-343 · Cited by 55
Tian, L., Altin, J. A., Makaroff, L. E., Franckaert, D., Cook, M. C., Goodnow, C. C., Dooley, J., & Liston, A. (2011) · Blood · doi:10.1182/blood-2011-04-346056 · Cited by 55
Utilizing Regulatory T Cells Against Rheumatoid Arthritis
Haque, M. M., Fino, K. K., Lei, F., Xiong, X., & Song, J. J. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00209 · Cited by 55
“Treg cells highly express CTLA-4, which controls the suppressive function of Treg cells (40).”
BackgroundRegulatory T Cells in Atherogenesis
Sasaki, N., Yamashita, T., Takeda, M., & Hirata, K. (2012) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.10934 · Cited by 55
Novel therapeutic targets in advanced urothelial carcinoma
Rouanne, M., Loriot, Y., Lebrét, T., & Soria, J. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.10.021 · Cited by 55
Zhao, H., Zhao, N., Zheng, P., Xu, X., Liu, M., Luo, D., Xu, H., & Ju, D. (2018) · Journal of Immunology Research · doi:10.1155/2018/6345857 · Cited by 56
Landuyt, A. E., Klocke, B. J., Colvin, T., Schoeb, T. R., & Maynard, C. L. (2019) · The Journal of Immunology · doi:10.4049/jimmunol.1801266 · Cited by 55
Harnessing Regulatory T Cells for the Treatment of Inflammatory Bowel Disease
Geem, D., Harusato, A., Flannigan, K. L., & Denning, T. L. (2015) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000000343 · Cited by 56
“For example, Foxp3+ Treg cell–specific ablation of CTLA-4 leads to a lymphoproliferative disease and multiorgan autoimmunity, whereas deletion of IL-10 in Foxp3+ Treg cells induces microbiota-driven colitis.(84,85) In line with these findings, polymorphisms in the genes for CTLA-4 and IL-10 receptor are associated wit…”
BackgroundProgrammed Cell Death 1-Directed Immunotherapy for Enhancing T-Cell Function
Araki, K., Youngblood, B., & Ahmed, R. (2013) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2013.78.019869 · Cited by 55
“CTLA-4 is also found on Tregs and plays an essential role in inhibitory functions of Tregs (Wing et al. 2008).”
BackgroundInfluentialDuraiswamy, J., Freeman, G. J., & Coukos, G. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2752 · Cited by 56
Kim, M. J., & Ha, S. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.767466 · Cited by 54
“Similar to other CD8 + T cells and Tconvs, Tregs express other ICRs in the TIME (Wing et al., 2008; Sakuishi et al., 2013; Kurtulus et al., 2015).”
BackgroundResultBulliard, Y., Freeborn, R. A., Uyeda, M. J., Humes, D. G., Bjordahl, R., VRIES, D. D., & Roncarolo, M. G. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1509956 · Cited by 54
Li, G., Che, X., Wang, S., Liu, D., Xie, D., Jiang, B., Zheng, Z., Xu, Z., & Wu, G. (2025) · Annals of Medicine · doi:10.1080/07853890.2024.2447403 · Cited by 55
Reduced Tregs in Peripheral Blood of PCOS Patients – a Consequence of Aberrant Il2 Signaling
Krishna, M. B., Joseph, A., Subramaniam, A. G., Gupta, A., Pillai, S. M., & Laloraya, M. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-2401 · Cited by 54
Jost, N. H., Abel, S., Hutzler, M., Sparwasser, T. D., Zimmermann, A., Roers, A., Müller, W., Klopfleisch, R., Hengel, H., Westendorf, A. M., et al. (2014) · Immunology and Cell Biology · doi:10.1038/icb.2014.62 · Cited by 54
Regulatory T cells suppress CD4+ T cells through NFAT‐dependent transcriptional mechanisms
Shin, D. S., Jordan, A., Basu, S., Thomas, R. M., Bandyopadhyay, S., de Zoeten, E. F., Wells, A. D., & Macián, F. (2014) · EMBO Reports · doi:10.15252/embr.201338233 · Cited by 55
“Several models have been proposed to explain how Tregs mediate suppression of T-cell activation [3], including secretion of immunomodulatory cytokines [4,5] and cell-to-cell contacts mediated by proteins such as CTLA-4 [6] or LAG-3 [7].”
Retseck, J., Nasr, A., Lin, Y., Lin, H., Mendiratta, P., Butterfield, L. H., & Tarhini, A. A. (2018) · Journal of Translational Medicine · doi:10.1186/s12967-018-1563-y · Cited by 51
Metadata
- Authors
- Wing, K., Onishi, Y., Prieto-Martin, P., Yamaguchi, T., Miyara, M., Fehervari, Z., Nomura, T., & Sakaguchi, S.
- Affiliations
- Tohoku University (JP)
- Department of Experimental Pathology, Institute for Frontier Medical Sciences, Kyoto University, Kyoto 606-8507, Japan.
- Corresponding author
- Wing, Kajsa
- Sakaguchi, Shimon
- Venue
- Science
- Published
- 2008-10-10
- Volume
- 322
- Issue
- 5899
- Pages
- 271-275
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2061071534
- Cited by
- 2,956
- References
- 25
- Citations by year
- 2026: 122 · 2025: 129 · 2024: 154 · 2023: 142 · 2022: 162 · 2021: 198 · 2020: 186 · 2019: 205 · 2018: 197 · 2017: 187 · 2016: 174 · 2015: 162 · 2014: 158 · 2013: 170 · 2012: 167
- FWCI
- 61.33
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- CTLA-4, Foxp3+ regulatory T cells, Treg suppressive function, lymphoproliferation, autoimmune disease, immunoglobulin E, antitumor immunity, dendritic cells, CD80, CD86, antigen presentation, immune tolerance
- MeSH terms
- Animals, Antigen-Presenting Cells, Autoimmune Diseases, Dendritic Cells, Female, Immunoglobulin E, Immunoglobulin G, Immune Tolerance, Leukemia, Lymphocyte Activation, Lymphocytes, Male, Mice, Inbred BALB C, Down-Regulation, Autoimmunity, Antigens, CD, B7-1 Antigen, CD8-Positive T-Lymphocytes, T-Lymphocytes, Regulatory, Mice, Forkhead Transcription Factors, B7-2 Antigen, CTLA-4 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.